Today’s Research Reports on Trillium Therapeutics, Canopy Growth, IntelliPharmaCeutics International and Aralez Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Trillium Therapeutics Inc.
https://rdinvesting.com/news/?ticker=TRIL.TO

Canopy Growth Corporation
https://rdinvesting.com/news/?ticker=WEED.TO

IntelliPharmaCeutics International Inc.
https://rdinvesting.com/news/?ticker=IPCI.TO

Aralez Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=ARZ.TO

Trillium Therapeutics’ stock moved 2.55% lower Monday, to close the day at $6.50. The stock recorded a trading volume of 2,955 shares, which was below its three months average volume of 5,420 shares. In the last year, Trillium Therapeutics’ shares have traded in a range of 5.26 – 16.80. The share price has gained 23.57% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $7.98 is below its 200-day moving average of $8.93. Shares of Trillium Therapeutics have fallen approximately 28.57 percent year-to-date.

Access RDI’s Trillium Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TRIL.TO

On Monday, shares of Canopy Growth recorded a trading volume of 2,747,823 shares, which was below the three months average volume of 5,061,628 shares. The stock ended the day 1.25% higher at 33.97. The share price has gained 306.34% from its 52 week low with a 52 week trading range of 8.36 – 48.72. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $38.22 is greater than its 200-day moving average of $33.25. Shares of Canopy Growth have gained approximately 14.22 percent year-to-date.

Access RDI’s Canopy Growth Corporation Research Report at:
https://rdinvesting.com/news/?ticker=WEED.TO

IntelliPharmaCeutics International’s stock jumped 8.54% Monday, to close the day at $0.445. The stock recorded a trading volume of 19,500 shares, which was above its three months average volume of 6,200 shares. In the last year, IntelliPharmaCeutics International’s shares have traded in a range of 0.41 – 1.72. The stock is currently trading 74.13% below its 52 week high. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $0.56 is below its 200-day moving average of $0.70. Shares of IntelliPharmaCeutics International have fallen approximately 54.55 percent year-to-date.

Access RDI’s IntelliPharmaCeutics International Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IPCI.TO

On Monday, shares of Aralez Pharmaceuticals recorded a trading volume of 33,795 shares, which was below the three months average volume of 150,919 shares. The stock ended the day 6.25% lower at 0.375. The share price has gained 29.31% from its 52 week low with a 52 week trading range of 0.29 – 3.72. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $0.467 is below its 200-day moving average of $1.428. Shares of Aralez Pharmaceuticals have fallen approximately 79.05 percent year-to-date.

Access RDI’s Aralez Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ARZ.TO

Our Actionable Research on Trillium Therapeutics Inc. (TSX :TRIL.TO) and Canopy Growth Corporation (TSX :WEED.TO) and IntelliPharmaCeutics International Inc. (TSX :IPCI.TO) and Aralez Pharmaceuticals Inc. (TSX :ARZ.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 507494